Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
retaspimycin + everolimus
- Development stage
- Unknown
- Lead developer
- Infinity Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Retaspimycin + everolimus is an investigational combination therapy consisting of **retaspimycin HCl (IPI-504)**, a potent small molecule inhibitor of **Heat Shock Protein 90 (Hsp90)**, and **everolimus**, a small molecule inhibitor of **mechanistic target of rapamycin (mTOR)**. This combination is being evaluated primarily for the treatment of solid tumors, specifically KRAS-mutant non-small cell lung cancer (NSCLC). Retaspimycin targets the chaperone protein Hsp90, leading to degradation of client oncoproteins, while everolimus allosterically inhibits mTORC1, suppressing cellular growth and proliferation pathways. This dual targeting approach aims to overcome resistance mechanisms linked to KRAS mutations and PI3K/mTOR pathway activation[1][4].
- Other names
- retaspimycin HCl + everolimus
02
Targets
Mechanistic target of rapamycin complex 1HSP90AA1 (Heat shock protein HSP90-alpha)
Beyond the preview
Go deeper on retaspimycin + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on retaspimycin + everolimus.